Peptide pills, supplements and nasal sprays: what the evidence and FDA say

Most peptides are broken down in the gut, so this page explains the few approved peptide tablets and nasal sprays, what supplement law allows, and why drug-named products are not those drugs.

Basics8 min read

Key takeaway

Swallowed peptides are mostly broken down by the digestive tract, so very few peptide medicines exist as pills. The approved semaglutide tablets need an absorption enhancer. Even so, the label estimates that only about 0.4% to 2% of the swallowed drug reaches the blood. FDA does not approve dietary supplements before they are sold. A "reta" pill is not retatrutide, which has no approved form of any kind.

At a glance

Article typeBasics
TopicPeptide science
Studies cited3
Related productsResearch peptide catalog

Most peptide supplements, pills and nasal sprays sold online have no FDA approval and little reliable human evidence that they work. The main reason starts in the gut, which breaks most peptides down before they can be absorbed. A few prescription medicines are real exceptions, and each one went through FDA review. This page explains the difference, what "dietary supplement" means in law, and why a product named after a drug is not that drug. Sources were checked on November 17, 2026.

Quick answer: For most products sold as peptide pills, capsules, drops or sprays, there is no good human evidence that they work. Products sold under names like retatrutide, BPC-157 or Semax are not FDA-approved medicines. The real peptide tablets and nasal sprays are prescription medicines with FDA labels, and a prescriber decides whether one fits. Research-grade peptides are laboratory reagents for laboratory research use only, not for human or veterinary use.

Why do most peptides fail as pills?

Peptides are short chains of amino acids, the same building blocks found in food protein. The stomach and intestine are built to break such chains down. A 2020 review of oral peptide drugs describes the digestive tract as a substantial barrier to them (Drucker, 2020). Developers use permeation enhancers, gut-enzyme inhibitors and other tricks to get around it. Our guide to how peptides work explains the chemistry.

Semaglutide tablets show how hard this is. Rybelsus and Ozempic tablets contain salcaprozate sodium (SNAC), which the FDA label calls an absorption enhancer. Even with SNAC, the label estimates that only 0.4% to 2% of the swallowed semaglutide reaches the bloodstream (DailyMed, 2026). Wegovy tablets, approved in December 2025, are another semaglutide tablet (Drugs@FDA).

All of these are prescription medicines. A licensed prescriber decides whether one fits and sets the dose from the FDA label. Our page on semaglutide and tirzepatide prescription labels explains how.

Table 1

Peptide pills, sprays and supplements: what FDA records show (checked November 17, 2026)

Product or name Form FDA status Source
Rybelsus and Ozempic tablets (semaglutide) Tablet with the absorption enhancer SNAC Approved; prescription Drugs@FDA
Wegovy tablets (semaglutide) Tablet Approved December 2025; prescription Drugs@FDA
Synarel (nafarelin) Nasal spray Approved; prescription Drugs@FDA
Desmopressin acetate; calcitonin-salmon Nasal sprays (generic versions) Approved; prescription Drugs@FDA; Drugs@FDA
Geref (sermorelin) Injectable only; no tablet listed Discontinued Drugs@FDA
Retatrutide No trial record describes an oral form Investigational; not a component of any approved drug FDA
BPC-157 Marketed as supplement capsules and tablets, and as sprays No approved product in any country FDA
Semax; Selank Marketed as nasal sprays Not FDA-approved; FDA says Semax is registered in Russia FDA
Collagen peptides Sold as supplements Supplements are not approved by FDA before sale FDA

Are collagen peptides different?

Collagen peptides are sold as supplements and food ingredients. They are made by breaking collagen from animal tissue into a mixture of short fragments, as our collagen peptides page describes. Some small fragments do reach the blood. In a 2005 study, a fragment called Pro-Hyp rose in volunteers' blood after they ate gelatin hydrolysates (Iwai et al., 2005).

Finding a fragment in blood is not proof of a benefit. A 2025 meta-analysis pooled 23 randomized trials of collagen supplements for aging skin (Myung and Park, 2025). All trials together showed improvements, but trials without pharmaceutical-company funding showed no effect. High-quality trials showed no significant effect either. The authors concluded there is currently no clinical evidence to support collagen supplements for preventing or treating skin aging.

What does "dietary supplement" mean for a peptide product?

A dietary supplement is a product meant to be swallowed that contains a dietary ingredient and is labeled as a supplement. FDA says it "does not have the authority to approve dietary supplements before they are marketed" (FDA, 2026). The company selling a supplement is responsible for its safety and labeling. A supplement also cannot claim to treat, cure or prevent a disease, because only a drug can legally make that claim. FDA adds that the supplement definition generally excludes ingredients approved as drugs, and in some cases ingredients being studied as drugs.

FDA's 2026 review of BPC-157 shows what this looks like in practice. FDA briefing materials say BPC-157 is marketed in the US as an ingredient in dietary supplement capsules and tablets (FDA, 2026). The same document says no approved product containing BPC-157 exists in any country. FDA also found no human pharmacokinetic data for BPC-157 taken by mouth or as a nasal spray. Our BPC-157 research summary covers the animal studies behind the claims.

FDA's health fraud guidance lists warning signs that fit many of these products. They include a product that "does it all," testimonials, quick fixes and "miracle cure" claims (FDA, 2021). FDA labs have found hundreds of weight-loss products, sold as supplements, that contained a hidden prescription drug ingredient. FDA's Health Fraud Product Database lists products named in its actions. FDA says the list is only a small fraction of hazardous products, so absence from it does not mean a product is safe.

Is a "reta" pill the same as retatrutide?

No. Retatrutide is an investigational drug from Eli Lilly. FDA says it is in no approved drug and has not been found safe and effective for any condition (FDA, 2026). On November 17, 2026, ClinicalTrials.gov listed 33 retatrutide study records, and none described an oral form (ClinicalTrials.gov, 2026). A product sold as a "reta" pill, supplement or drop is not the drug studied in those trials.

FDA has also warned companies that sold retatrutide and other GLP-1 products falsely labeled for research or "not for human consumption" directly to consumers. Our page on whether retatrutide is legal lists those letters. In March 2026, FDA sent online advisory letters about liquids, drops and a patch sold with "GLP-1" in their names (FDA, 2026). FDA sends these letters to companies illegally marketing products to treat or prevent serious diseases.

Lilly does have an approved GLP-1 tablet, but it is a different medicine. Foundayo, approved in April 2026, contains orforglipron and is a prescription tablet (Drugs@FDA). Its label covers weight reduction in adults with obesity, or overweight with a weight-related condition, alongside diet and activity (DailyMed, 2026).

Is there a sermorelin pill?

No. Drugs@FDA lists sermorelin only under the brand Geref, as injectable products that are now discontinued (Drugs@FDA). No sermorelin tablet or capsule appears there. In 2013, FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness (Federal Register, 2013). That finding is about the old approved product, not anything sold under the sermorelin name today.

Do peptide nasal sprays work?

Some do, as prescription medicines tested for specific conditions. Drugs@FDA lists nasal sprays of nafarelin (Synarel), desmopressin acetate and calcitonin-salmon with the marketing status "Prescription" (Table 1). Each has an FDA label for its approved uses, and a prescriber decides whether it fits.

The peptide nasal sprays sold online are a different story. FDA's 2026 briefing says Semax injection and nasal products are widely marketed in the US by clinics and online retailers (FDA, 2026). It says "Semax is a registered drug in Russia" and that Semax is not a component of an FDA-approved drug. FDA's evaluation weighed against adding it to the list of substances pharmacies may compound with. FDA cited possible immune reactions, from aggregation and impurities, in both injectable and nasal spray forms.

FDA's compounding safety-risks page lists Selank acetate among substances nominated and later withdrawn. It says FDA "lacks important information" about safety issues with Selank acetate in humans (FDA, 2026). Our Semax research summary covers the small studies behind these names.

What should you do if you already bought or used one?

  • Talk to a professional. Show the product and its label to a licensed clinician or pharmacist, and tell them what you took.
  • Report problems. Report side effects or product problems to FDA through MedWatch, online or by calling 1-888-INFO-FDA (1-888-463-6332) and pressing 2.
  • Emergencies. If someone collapses, has a seizure or has trouble breathing, call 911. For a possible poisoning, call Poison Help at 1-800-222-1222 (Poison Control).
  • Fraud. Report a product you think is fraudulent through FDA's problem-reporting page.

To judge a claim you saw in an ad, see how to evaluate peptide research. If you buy medicine online, read our guide to counterfeit GLP-1 medicines and illegal online pharmacies.

Frequently asked questions about peptide pills, supplements and nasal sprays

Do peptide supplements work?

For most products sold as peptide supplements, there is no good human evidence that they work. FDA does not approve dietary supplements before they are sold. A 2025 meta-analysis also found no effect of collagen supplements on skin aging in high-quality trials.

Is there a retatrutide pill?

No. Retatrutide has no FDA-approved form, and none of its 33 ClinicalTrials.gov records describes an oral form. A "reta" pill or supplement is not the drug studied in Lilly's trials.

Does oral BPC-157 work?

There is no human evidence that it does. FDA's 2026 review found no human pharmacokinetic data for BPC-157 taken by mouth, and no approved BPC-157 product exists in any country.

Is there a sermorelin pill?

No. The only FDA-approved sermorelin product was Geref, an injectable that is now discontinued, and no sermorelin tablet or capsule appears in Drugs@FDA.

Do peptide nasal sprays work?

A few prescription peptide nasal sprays, such as nafarelin and desmopressin, are FDA-approved for specific conditions. Sprays sold online under names like Semax, Selank or BPC-157 are not FDA-approved, and FDA has raised safety and evidence concerns about them.

Are Semax and Selank nasal sprays approved in the US?

No. FDA briefing materials say Semax is registered as a drug in Russia but is not a component of any FDA-approved drug. FDA says it lacks important information about the safety of Selank acetate in humans.

What to know now

  • Digestion: the gut breaks down most peptides, so real peptide tablets need special formulation.
  • Approved exceptions: semaglutide tablets and a few nasal sprays, all by prescription.
  • Supplements: FDA does not approve them before sale, and they cannot claim to treat disease.
  • Drug-named products: a "reta" pill is not retatrutide, and BPC-157 has no approved product anywhere.
  • Nasal sprays online: Semax and Selank are not FDA-approved.
  • Research grade: laboratory reagents for laboratory research use only, not for human or veterinary use.

What we're watching

FDA's final decisions on BPC-157, Semax and the other peptides. We also track new FDA letters to sellers of drug-named supplements, and any oral peptide medicines that reach approval.

Also in the library

Sources: Drucker 2020, Nature Reviews Drug Discovery; National Library of Medicine. DailyMed: Rybelsus and Ozempic (semaglutide) tablets, DailyMed: Rybelsus and Ozempic (semaglutide) tablets, Novo Nordisk; U.S. Food and Drug Administration. Drugs@FDA: NDA 213051 (Rybelsus and Ozempic tablets) and NDA 218316 (Wegovy tablets) . https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051 ; https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316, Drugs@FDA: NDA 213051 (Rybelsus and Ozempic tablets) and NDA 218316 (Wegovy tablets); Iwai 2005, Journal of Agricultural and Food Chemistry; Myung 2025, American Journal of Medicine; U.S. Food and Drug Administration 2026, Questions and answers on dietary supplements; U.S. Food and Drug Administration 2021, 6 tip-offs to rip-offs: Don't fall for health fraud scams; U.S. Food and Drug Administration. Health fraud product database . https://www.fda.gov/consumers/health-fraud-scams/health-fraud-product-database, Health fraud product database; U.S. Food and Drug Administration 2026; U.S. Food and Drug Administration 2026; U.S. Food and Drug Administration 2026; U.S. Food and Drug Administration 2026, FDA's concerns with unapproved GLP-1 drugs used for weight loss; National Library of Medicine. ClinicalTrials.gov: studies with retatrutide as an intervention (searched November 17, ClinicalTrials.gov: studies with retatrutide as an intervention; U.S. Food and Drug Administration 2026, Online advisory letters; U.S. Food and Drug Administration and National Library of Medicine. Drugs@FDA: NDA 220934 (Foundayo); DailyMed: Foundayo (orforglipron) tablets; U.S. Food and Drug Administration. Drugs@FDA: NDA 020443 (Geref) . https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020443, Drugs@FDA: NDA 020443 (Geref); Food and Drug Administration 2013, Federal Register; U.S. Food and Drug Administration. Drugs@FDA: NDA 019886 (Synarel); U.S. Food and Drug Administration 2025, Reporting serious problems to FDA (MedWatch); National Capital Poison Center. Poison Control (Poison Help line 1-800-222-1222). https://www.poison.org/, Poison Control. All 20 citations

Back to the research library

References

  1. Drucker, D. J. (2020). Advances in oral peptide therapeutics. Nature Reviews Drug Discovery, 19(4), 277-289. https://pubmed.ncbi.nlm.nih.gov/31848464/
  2. National Library of Medicine. DailyMed: Rybelsus and Ozempic (semaglutide) tablets, Novo Nordisk (revised January 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  3. U.S. Food and Drug Administration. Drugs@FDA: NDA 213051 (Rybelsus and Ozempic tablets) and NDA 218316 (Wegovy tablets). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051; https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316
  4. Iwai, K., et al. (2005). Identification of food-derived collagen peptides in human blood after oral ingestion of gelatin hydrolysates. Journal of Agricultural and Food Chemistry, 53(16), 6531-6536. https://pubmed.ncbi.nlm.nih.gov/16076145/
  5. Myung, S. K., and Park, Y. (2025). Effects of collagen supplements on skin aging: A systematic review and meta-analysis of randomized controlled trials. American Journal of Medicine, 138(9), 1264-1277. https://pubmed.ncbi.nlm.nih.gov/40324552/
  6. U.S. Food and Drug Administration. (2026). Questions and answers on dietary supplements (content current as of August 27, 2026). https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements
  7. U.S. Food and Drug Administration. (2021). 6 tip-offs to rip-offs: Don't fall for health fraud scams. https://www.fda.gov/consumers/consumer-updates/6-tip-offs-rip-offs-dont-fall-health-fraud-scams
  8. U.S. Food and Drug Administration. Health fraud product database. https://www.fda.gov/consumers/health-fraud-scams/health-fraud-product-database
  9. U.S. Food and Drug Administration. (2026). FDA briefing document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: BPC-157-related bulk drug substances. https://www.fda.gov/media/193343/download
  10. U.S. Food and Drug Administration. (2026). FDA briefing document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: Semax-related bulk drug substances. https://www.fda.gov/media/193348/download
  11. U.S. Food and Drug Administration. (2026). Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  12. U.S. Food and Drug Administration. (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  13. National Library of Medicine. ClinicalTrials.gov: studies with retatrutide as an intervention (searched November 17, 2026). https://clinicaltrials.gov/search?intr=retatrutide
  14. U.S. Food and Drug Administration. (2026). Online advisory letters (content current as of June 30, 2026). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/online-advisory-letters
  15. U.S. Food and Drug Administration and National Library of Medicine. Drugs@FDA: NDA 220934 (Foundayo); DailyMed: Foundayo (orforglipron) tablets, Eli Lilly and Company. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220934; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
  16. U.S. Food and Drug Administration. Drugs@FDA: NDA 020443 (Geref). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020443
  17. Food and Drug Administration. (2013, March 4). Determination that GEREF (sermorelin acetate) injection products were not withdrawn from sale for reasons of safety or effectiveness. Federal Register, 78 FR 14095. https://www.federalregister.gov/documents/2013/03/04/2013-04827/
  18. U.S. Food and Drug Administration. Drugs@FDA: NDA 019886 (Synarel), ANDA 091345 (desmopressin acetate nasal spray), ANDA 076396 (calcitonin-salmon nasal spray). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019886
  19. U.S. Food and Drug Administration. (2025). Reporting serious problems to FDA (MedWatch). https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/reporting-serious-problems-fda
  20. National Capital Poison Center. Poison Control (Poison Help line 1-800-222-1222). https://www.poison.org/